Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 5/20 | 0.40 |
| ▸ | JAK3 | P52333 | 5/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.38 |
| ▸ | INSR | P06213 | 3/20 | 0.38 |
| ▸ | BTK | Q06187 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | CDC7 | O00311 | 2/20 | 0.38 |
| ▸ | PLK4 | O00444 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | PAK4 | O96013 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1605710 | 0.93 | JAK3 (0.43) | PKMYT1AURKAEGFRJAK3PTK2 | |
| SCHEMBL1607534 | 0.92 | ALK (0.47) | AURKAEGFRJAK3PTK2CDK2 | |
| SCHEMBL1608189 | 0.89 | JAK2 (0.49) | PKMYT1AURKAEGFRJAK3PTK2 | |
| SCHEMBL1605651 | 0.89 | ALK (0.46) | PKMYT1AURKAEGFRJAK3PTK2 | |
| SCHEMBL1606308 | 0.87 | PTK2 (0.52) | AURKAEGFRJAK3PTK2CDK2 | |
| SCHEMBL1606991 | 0.86 | ALK (0.47) | PKMYT1AURKAEGFRJAK3PTK2 | |
| SCHEMBL1607097 | 0.85 | ALK (0.54) | AURKAEGFRJAK3PTK2CDK2 | |
| SCHEMBL1606725 | 0.85 | AURKA (0.45) | AURKAEGFRJAK3PTK2ALK | |
| SCHEMBL1606952 | 0.84 | INSR (0.53) | AURKAEGFRJAK3PTK2CDK2 | |
| SCHEMBL1606288 | 0.83 | EGFR (0.52) | PKMYT1AURKAEGFRJAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304422-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | claimed |
| US-7947698-B2 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-20110082146-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | claimed |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | claimed |
| US-8304422-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-7947698-B2 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110082146-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008118822-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082146-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | PKMYT1 1718/4885AURKA 751/4885EGFR 529/4885 |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | PKMYT1 1170/4885AURKA 3610/4885EGFR 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.